Moderna jumped more than 12% after sharing encouraging updates on its pipeline, including new cancer and autoimmune treatments. Investors are looking beyond COVID vaccines and focusing on the company's long-term growth potential. Now the focus shifts to upcoming clinical results and regulatory decisions.
#ModernaRisesOver12%